SRR8752371
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
- ANGIOGENESIS+0.420
- HEDGEHOG_SIGNALING+0.400
- ALLOGRAFT_REJECTION+0.390
- APICAL_SURFACE+0.370
- APICAL_JUNCTION+0.340
- INFLAMMATORY_RESPONSE+0.330
- IL2_STAT5_SIGNALING+0.310
- PANCREAS_BETA_CELLS+0.300
- TNFA_SIGNALING_VIA_NFKB+0.280
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.400
- MYC_TARGETS_V1-0.350
- MYC_TARGETS_V2-0.340
- E2F_TARGETS-0.310
- FATTY_ACID_METABOLISM-0.290
- G2M_CHECKPOINT-0.290
- DNA_REPAIR-0.250
- ADIPOGENESIS-0.210
- PEROXISOME-0.170
- PROTEIN_SECRETION-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202494 | — | — | 0.910 |
| 2 | 21196229-e39e-4846-be58-a1055b3ae50e | — | — | 0.904 |
| 3 | f22cfa82-a346-4fed-bc81-21a29bf990ee | — | — | 0.903 |
| 4 | SRR15069612 | — | — | 0.891 |
| 5 | TCGA-63-7022-01A-11R-1949-07 | — | cohortSQ1 | 0.888 |
| 6 | 4925248f-21e2-476e-937c-02e0a748c77b | — | — | 0.885 |
| 7 | 94f6e4f5-2447-4f1f-9f36-411f1c25a172 | — | — | 0.882 |
| 8 | e074ff82-1def-4bfc-8293-6b69f8984046 | — | — | 0.882 |
| 9 | TCGA-4Z-AA7N-01A-11R-A39I-07 | — | — | 0.882 |
| 10 | ffe7358d-31b2-4d92-93eb-0a88abaf2dca | — | — | 0.882 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.530 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.420 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.400 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.390 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.370 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.340 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.330 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.310 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.280 | Inavolisib | — uncovered |
| COMPLEMENT | 0.270 | Inavolisib | — uncovered |
| MYOGENESIS | 0.240 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| COAGULATION | 0.190 | Binimetinib | — uncovered |